Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Who May Qualify: - ≥18 years of age. - Newly diagnosed multiple myeloma. - Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1. - Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner. - Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy. Who Should NOT Join This Trial: - History of previous treatment for MM. - Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. - Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis. - Severe active infection secondary to viruses, bacteria or fungi. - Pulmonary disease requiring supplemental oxygen. - History of allogeneic or autologous hematopoietic cell transplantation. - Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration. - Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery. - Presence of other concomitant malignancy. - Hepatitis B and C virus infection or human weakened immune system virus (HIV) infection. - Cerebrovascular events or seizures in the last 6 months. - Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage). - Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months. - Women of childbearing age: active pregnancy prior to the first administration of treatment. Always talk to your doctor about whether this trial is right for you.